Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)...
BOSTON, June 07, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of lead product candidate …